Advancing small molecule CXCR4 agonists for diabetic wound healing

推进小分子 CXCR4 激动剂促进糖尿病伤口愈合

• 批准号: 10629155
• 负责人: KENNETH W LIECHTY
• 金额: $ 46.99万
• 依托单位: UNIVERSITY OF ARIZONA
• 依托单位国家: 美国
• 财政年份: 2023
• 资助国家: 美国
• 起止时间: 2023-03-15 至 2025-05-31
• 项目状态: 未结题
• 来源: https://reporter.nih.gov/project-details/10629155
• 关键词: Acceleration; Agonist; Amputation; Animals; Architecture; Area; Binding; Biological Assay; CXCR4 Receptors; CXCR4 Signaling Pathway; CXCR4 gene; Chemotaxis; Clinical; Collagen; Data; Diabetes Mellitus; Drug Kinetics; Epidemic; Epithelium; Fibroblasts; Formulation; Gene Expression; Goals; Granulation Tissue; Health Expenditures; Histology; Human; Immunohistochemistry; Impaired wound healing; Impairment; In Vitro; Individual; Inflammation; Injections; Lead; Libraries; Lower Extremity; Measurement; Measures; Mediating; Messenger RNA; MicroRNAs; Migration Assay; Mus; Oxazoles; Pathway interactions; Patient-Focused Outcomes; Permeability; Pharmaceutical Chemistry; Production; Proteins; Research; Series; Skin; Skin wound healing; Societies; Structure-Activity Relationship; Testing; Toxic effect; United States; United States National Institutes of Health; Western Blotting; Work; Wound models; analog; angiogenesis; chemokine; clinical application; clinically relevant; commercialization; counterscreen; diabetic; diabetic patient; diabetic ulcer; diabetic wound healing; effective therapy; healing; improved; in vivo; lead optimization; metabolic abnormality assessment; migration; mouse model; non-healing wounds; novel; novel therapeutics; porcine model; pre-clinical; recruit; scaffold; screening; small molecule; small molecule therapeutics; stem cells; wound; wound closure; wound healing

Project Summary/Abstract Diabetes has reached epidemic proportions in the United States and globally, and impaired diabetic wound healing is a significant and growing clinical problem. The long-term goal of our research is to develop small molecule therapeutics to effectively promote healing of diabetic wounds. Diabetic wounds are deficient in stromal derived factor-1α (SDF-1α), a potent chemokine involved in progenitor cell recruitment, angiogenesis, and granulation tissue formation, mediated through binding to the CXCR4 receptor and the establishment of a chemotactic gradient. Our previous research data confirmed that targeting SDF-1α/CXCR4 signaling pathway has great potential to improve diabetic wound healing. Therefore, screening small molecule agonists that can activate CXCR4 receptor and its downstream pathway will provide a novel therapy for diabetic wound healing, and has great potential for clinical application and commercialization. In our previous RO1 (R01DK105010, Identifying CXCR4 receptor agonists to improve diabetic wound healing), we screened the entire NIH SMR library of >370k molecules using our robust testing funnel and identified 303 lead compounds. These lead compounds were further validated with by counter-screen, secondary chemotaxis/migration assays, and their ability to correct abnormal expression of microRNA-146a, 15b, and 29a, resulting in the identification of 2 lead scaffolds. In an exciting preliminary study we tested the ability of our lead scaffold CAG1 to improve diabetic wound healing following injection into murine diabetic wounds. We found that a single CAG1 injection resulted in a significant improvement in the rate of diabetic wound closure, but the optimal formulation and mechanisms of correction remain to be determined. The objective of this work is to determine the ability of our novel small molecule CXCR4 agonists to correct the diabetic wound healing impairment in vivo, optimize the formulation and pharmacokinetics in vitro and in vivo using a medicinal chemistry approach, determine the mechanisms of action, and then extend these observations to the clinically relevant porcine model. The following Specific Aims are proposed: Specific aim 1: Conduct lead optimization of the 5-aryl oxazole and triazolo thiadiazine series using structure- activity- relationship medicinal chemistry approaches, Determine compound in vitro EC50 values in primary and functional assays, KD values in a CXCR4 binding assay and determine effect on human diabetic fibroblast expression of miR15b, and miR29a. Specific aim 2: Perform in vitro stability, skin permeability and metabolism studies and determine the mechanisms of diabetic wound healing correction in a murine model of wound healing for compounds advancing to tier 4. Specific aim 3: Identify a CAG1 or CAG2 lead compound in tier 5 and Validate that CXCR4 agonist corrects the diabetic wound healing impairment and is non-toxic in a pre-clinical porcine model.

项目摘要/摘要 糖尿病已在美国和全球达到流行病，糖尿病伤口受损 康复是一个重大且不断增长的临床问题。我们研究的长期目标是发展小 分子理论有效地促进糖尿病伤口的愈合。糖尿病伤口不足 基质衍生因子1α（SDF-1α），一种参与祖细胞募集，血管生成的有效趋化因子， 和肉芽组织形成，通过与CXCR4受体结合并建立A介导 趋化梯度。我们以前的研究数据证实，针对SDF-1α/CXCR4信号通路 具有改善糖尿病伤口愈合的巨大潜力。因此，筛选小分子激动剂可以 激活CXCR4受体及其下游途径将为糖尿病伤口愈合提供新的疗法， 并具有临床应用和商业化的巨大潜力。在我们以前的RO1（R01DK105010， 确定CXCR4受体激动剂以改善糖尿病伤口愈合），我们筛选了整个NIH SMR 使用我们可靠的测试漏斗的> 370K分子的库，并确定了303种铅化合物。这些领导 通过反屏幕，次级趋化/迁移测定法进一步证实化合物，它们 绝对要纠正microRNA-146a，15b和29a的异常表达，从而识别2个铅 脚手架。在一项令人兴奋的初步研究中，我们测试了铅支架CAG1改善糖尿病的能力 注射到鼠糖尿病伤口后的伤口愈合。我们发现导致单个CAG1注射 糖尿病伤口闭合率有显着提高，但最佳公式和机制 校正仍有待确定。这项工作的目的是确定我们小说的小小的能力 分子CXCR4激动剂纠正体内糖尿病伤口愈合障碍，优化公式 使用医学化学方法在体外和体内的药代动力学，确定 作用，然后将这些观察结果扩展到临床相关的猪模型。以下特定 提出了目的：特定目标1：进行5-芳基恶唑和三唑的铅优化 噻二嗪系列使用结构 - 活动相关药物化学方法，确定 基本和功能分析中的体外EC50值，CXCR4结合测定中的KD值 并确定对miR15b和miR29a的人类糖尿​​病成纤维细胞表达的影响。具体目标2： 进行体外稳定性，皮肤渗透性和代谢研究，并确定 鼠伤口愈合模型的糖尿病伤口愈合矫正，用于前进的化合物 第4层。特定目标3：识别第5层中的CAG1或CAG2铅化合物并验证该CXCR4 激动剂纠正糖尿病伤口愈合障碍，在临床前猪中无毒 模型。

项目成果

Discovery of Small Molecule Activators of Chemokine Receptor CXCR4 That Improve Diabetic Wound Healing.

发现可改善糖尿病伤口愈合的趋化因子受体 CXCR4 小分子激活剂。

• DOI: 10.3390/ijms23042196
• 发表时间: 2022-02-16
• 期刊: International journal of molecular sciences
• 影响因子: 5.6
• 作者: Xu J;Hu J;Idlett-Ali S;Zhang L;Caples K;Peddibhotla S;Reeves M;Zgheib C;Malany S;Liechty KW
• 通讯作者: Liechty KW